← All trials
NCT04964544
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 8, 2021
- Primary completion
- Feb 20, 2023
- Completion date
- Feb 20, 2023
- First posted
- Jul 16, 2021
- Last posted
- Nov 26, 2021
- Enrollment
- 1220
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- The Cleveland ClinicCollaborator
- Concentrics ResearchCollaborator
- Concentrics ResearchCollaborator
- Concentrics ResearchOverall official - principal investigator
- Idea EvolverCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.